310
Participants
Start Date
November 22, 2022
Primary Completion Date
November 30, 2026
Study Completion Date
June 30, 2027
TYRA-300
TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.
RECRUITING
Macquarie University, Macquarie Park
RECRUITING
Peter MacCallum Cancer Research Unit, Melbourne
RECRUITING
Austin Health, Heidelberg
RECRUITING
Princess Alexandra Hospital, Woolloongabba
RECRUITING
Tasman Oncology, Southport
RECRUITING
Linear Clinical Research Limited, Nedlands
RECRUITING
Memorial Sloan Kettering Cancer Center (MSKCC), New York
RECRUITING
Duke Cancer Institute (DCI) - Duke Cancer Center, Durham
RECRUITING
NEXT Madrid - Hospital Universitario Quironsalud Madrid, Madrid
WITHDRAWN
Prisma Health Cancer Institute - Faris, Greenville
RECRUITING
Institut Claudius Regaud, IUCT-Oncopole, Toulouse
WITHDRAWN
Florida Cancer Affiliates - Ocala - Main (Ocala Oncology - Ocala), Ocala
RECRUITING
Vanderbilt University Medical Center (VUMC) - Vanderbilt-Ingram Cancer Center (VICC) - Nashville, Nashville
RECRUITING
Cleveland Clinic - Main Campus, Cleveland
RECRUITING
Institut de Cancerologie de L'Ouest (ICO), Saint-Herblain
RECRUITING
Gustave Roussy (Institut de Cancerologie Gustave-Roussy), Villejuif
RECRUITING
Seattle Cancer Care Alliance (SCCA) - South Lake Union, Seattle
RECRUITING
Dana Farber Cancer Institute, Boston
RECRUITING
UMass Memorial Medical Center, Worcester
RECRUITING
NEXT Barcelona - Hospital Quironsalud Barcelona, Barcelona
RECRUITING
Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona
Tyra Biosciences, Inc
INDUSTRY